Merck KGaA Deal Gives Diaccurate New Lead Cancer Candidate
Biotech Targets Triple-Negative Breast Cancer and Lymphoma
Executive Summary
The Paris-based biotech was chosen to take the compound forward, with Merck KGaA also taking a stake in the company.
You may also be interested in...
Deal Watch: AzurRx Expands GI Pipeline With Buyout Of Partner First Wave
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
Merck KGaA In The Market For Bolt-On M&A
Belén Garijo, the German group's CEO, has told analysts she considers targeted smaller to medium-sized acquisitions to be more likely than major transformational deals but said that "we are always open to something bolder."
Another Activist Investor Joins Calls For GSK Leadership Review
A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO, and has underlined competitive threats to a key pipeline candidate.